Advertisement

Drug Safety

pp 1–1 | Cite as

Correction to: Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes

  • Marek MalikEmail author
  • Christine Garnett
  • Katerina Hnatkova
  • Jose Vicente
  • Lars Johannesen
  • Norman Stockbridge
Open Access
Correction
  • 53 Downloads

1 Correction to: Drug Safety  https://doi.org/10.1007/s40264-018-0735-2

The Open Access license, which previously read:

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Should read:

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.National Heart and Lung Institute, Imperial CollegeLondonUK
  2. 2.Division of Cardiovascular and Renal Products, Office of New DrugsCenter for Drug Evaluation and Research, US Food and Drug AdministrationSilver SpringUSA
  3. 3.Division of Clinical Pharmacology I, Office of Clinical PharmacologyCenter for Drug Evaluation and Research, US Food and Drug AdministrationSilver SpringUSA

Personalised recommendations